B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart

Cardiovascular Research

Volumn 80, Issue 1, 2008, Pages 106-113

  Sanchez De Miguel, Lourdes ^a   Neysari, Shiva ^a   Jakob, Sonja ^a   Petrimpol, Marco ^a   Butz, Nicole ^a   Banfi, Andrea ^a   Zaugg, Christian E ^b   Humar, Rok ^a,c   Battegay, Edouard J ^a,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ACE inhibition; Angiogenesis; Heart; Hypoxia; Kinins

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; ENALAPRIL; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 14; ICATIBANT; KALLIKREIN INHIBITOR; NITRIC OXIDE; PERINDOPRIL; PKSI 527; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 164; VASCULOTROPIN INHIBITOR; ZM 323881;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; C57BL 6 MOUSE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SPROUTING; WESTERN BLOTTING; WILD TYPE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANOXIA; BRADYKININ; ENALAPRIL; FIBROBLAST GROWTH FACTORS; HEART; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51749098578     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn170     Document Type: Article

References (42)

1. Li K, Chen X. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 1987;19:909-915.
2. Xia CF, Smith RS Jr, Shen B, Yang ZR, Borlongan CV, Chao L et al. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 2006;47:752-761.
3. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999;99:3043-3049.
4. Tanonaka K, Kamiyama T, Takezono A, Sakai K, Takeo S. Beneficial effects of angiotensin I converting enzyme inhibitor on post-ischemic contractile function of perfused rat heart. J Mol Cell Cardiol 1996;28:1659- 1670.
5. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970;214:374-376.
6. Olivetti G, Cigola E, Lagrasta C, Ricci R, Quaini F, Monopoli A et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993;21:362-370.
7. Allogho SN, Gobeil F, Pheng LH, Nguyen-Le XK, Neugebauer W, Regoli D. Kinin B1 and B2 receptors in the mouse. Can J Physiol Pharmacol 1995;73:1759-1764.
8. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2001;429:161-176.
9. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77.
10. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001;89:678-683.
11. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 2005;25:65-70.
12. Ishihara K, Kamata M, Hayashi I, Yamashina S, Majima M. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol 2002;2:499-509.
13. Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, Ishihara K et al. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004;64:5178-5185.
14. Munk VC, de Miguel LS, Petrimpol M, Butz N, Banfi A, Eriksson U et al. Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an AT2-B2 receptor pathway. Hypertension 2007;49:1178-1185.
15. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 2001;15:1487-1489.
16. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001;103:125-132.
17. Hayashi I, Amano H, Yoshida S, Kamata K, Kamata M, Inukai M et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest 2002;82:871-880.
18. Plendl J, Snyman C, Naidoo S, Sawant S, Mahabeer R, Bhoola KD. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem 2000;381:1103-1115.
19. Kiefer FN, Munk VC, Humar R, Dieterle T, Landmann L, Battegay EJ. A versatile in vitro assay for investigating angiogenesis of the heart. Exp Cell Res 2004;300:272-282.
20. Munk VC, Sanchez de Miguel L, Humar R, Kiefer FN, Butz N, Battegay EJ. iNOS is required for in vitro angiogenesis of hypoxic mouse hearts. Semin Cardiol 2006;12:21-26.
21. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993;214:11-16.
22. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 2007;100:79-87.
23. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 1994;28:1176-1179.
24. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-846.
25. Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, Vogt B et al. Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 2003;14:2861-2872.
26. Wirth KJ, Wiemer G, Scholkens BA. DesArg10[Hoe 140] is a potent B1 bradykinin antagonist. Agents Actions Suppl 1992;38:406-413.
27. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in strokeprone spontaneously hypertensive rats. Hypertension 1997;29:478-482.
28. Donnini S, Solito R, Giachetti A, Granger HJ, Ziche M, Morbidelli L. Fibroblast growth factor-2 mediates angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium. J Pharmacol Exp Ther 2006;319:515-522.
29. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG. Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem 2002;277:16847-16852.
30. Benzing T, Fleming I, Blaukat A, Muller-Esterl W, Busse R. Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999;99:2034-2040.
31. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 2006;48:316-322.
32. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000;407:94-98.
33. Kang DS, Ryberg K, Morgelin M, Leeb-Lundberg LM. Spontaneous formation of a proteolytic B1 and B2 bradykinin receptor complex with enhanced signaling capacity. J Biol Chem 2004;279:22102-22107.
34. Miura S, Matsuo Y, Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003;41:1118-1123.
35. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 2002;277:2028-2032.
36. Kondo T, Kobayashi K, Murohara T. Nitric oxide signaling during myocardial angiogenesis. Mol Cell Biochem 2004;264:25-34.
37. Kiefer FN, Misteli H, Kalak N, Tschudin K, Fingerle J, Van der Kooij M et al. Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension. Blood Press 2002;11:116-124.
38. Steinhauff S, Pehlivanli S, Bakovic-Alt R, Meiser BM, Becker BF, von Scheidt W et al. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Transplantation 2004;77:1859-1865.
39. Maestri R, Milia AF, Salis MB, Graiani G, Lagrasta C, Monica M et al. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 2003;41:1151-1155.
40. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N et al. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 1997;96:3570-3578.
41. Yang XP, Liu YH, Mehta D, Cavasin MA, Shesely E, Xu J et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res 2001;88:1072-1079.
42. Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV et al. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 2008;51:454-459.